Sarcoma
Brightline-4
Official Title: Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of brigimadlin (BI 907828) treatment in patients with treatment-naïve or pre-treated advanced dedifferentiated liposarcoma
Study Purpose: The primary objective is to evaluate the safety of brigimadlin in patients with advanced or metastatic DDLPSThe secondary objectives are to evaluate efficacy by using objective response (OR), duration of objective response (DOR), PFS, and overall survival (OS), and to further assess safety.
Status:
Suspended